Oncology
Page 6 • 7 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
TME Pharma NOX-A12 Triple Therapy Shows Promise in Brain Cancer GLORIA Trial Published in Nature Communications
TME Pharma announces Nature Communications publication of NOX-A12 triple therapy Phase 1/2 GLORIA trial results for brain cancer treatment.
Boehringer Ingelheim and Zai Lab Launch Phase Ib/II Trial for DLL3-Targeting Combination Therapy in Small Cell Lung Cancer
Boehringer Ingelheim partners with Zai Lab to test obrixtamig plus zocilurtatug pelitecan combination in Phase Ib/II trial for SCLC and neuroendocrine carcinomas.
Medicenna's Bizaxofusp Shows Promise in Brain Cancer Trials Ahead of 2026 Investor Conference
Medicenna's bizaxofusp demonstrates clinical progress in glioblastoma trials with FDA FastTrack status, positioning for major investor presentation in 2026.
GlycoNex GNX1021 Gets PMDA Approval for First-in-Human Phase 1 Trial in Gastrointestinal Cancers
GlycoNex receives PMDA approval to begin first-in-human Phase 1 trial of GNX1021 antibody-drug conjugate for advanced gastrointestinal cancers in Japan.
CHMP Positive Opinion Immunotherapy: Expanded Use in Advanced Lung Cancer
The CHMP's positive opinion on [Drug Name] marks a significant step towards expanded immunotherapy options for patients with advanced lung cancer.
EMA Conditional Approval CAR-T Therapy for Relapsed B-Cell Lymphoma
The EMA has granted conditional approval for CAR-T therapy, offering new hope for patients with relapsed B-cell lymphoma.
CHMP Positive Opinion CAR-T Therapy: What You Need to Know
The CHMP has issued a positive opinion for CAR-T therapy, a groundbreaking treatment for specific blood cancers, offering new hope for patients.